Towards personalized therapy for patients with malignant melanoma: Molecular insights into the biology of BRAF mutations

Future Oncology

Volumn 9, Issue 2, 2013, Pages 245-253

  Bradish, Joshua R ^a   Montironi, Rodolfo ^b   Lopez Beltran, Antonio ^c   Post, Kristin M ^a   MacLennan, Gregory T ^d   Cheng, Liang ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c Universidad de Cordoba   (Spain)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRAF mutation; KIT mutation; malignant melanoma; metastasis; NRAS mutation; pathway targeting; personalized medicine; targeted therapy

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; DABRAFENIB; DACARBAZINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NRAS PROTEIN; RAS PROTEIN; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; VEMURAFENIB;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROLIFERATION; DISEASE FREE SURVIVAL; DRUG RESPONSE; GENE FREQUENCY; GENE LOCATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; INCIDENCE; MELANOCYTE; MELANOCYTIC NEVUS; MELANOMA; MUTATIONAL ANALYSIS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN LOCALIZATION; REVIEW;

DRUG RESISTANCE, NEOPLASM; GTP PHOSPHOHYDROLASES; HUMANS; INDIVIDUALIZED MEDICINE; MELANOMA; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84874028989     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.179     Document Type: Review

References (40)

1. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J. Invest. Dermatol. 129, 1666-1674 (2009).
2. Ascierto PA, Kirkwood JM, Grob JJ et al. The role of BRAF V600 mutation in melanoma. J. Transl. Med. 10, 85 (2012).
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
4. Jemal A, Saraiya M, Patel P et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. J. Am. Acad. Dermatol. 65(5 Suppl. 1), S17-S25.e1-3 (2011).
5. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012. CA Cancer J. Clin. 62, 10-29 (2012).
6. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199-6206 (2009).
7. Katona TM, Jones TD, Wang M, Eble JN, Billings SD, Cheng L. Genetically heterogeneous and clonally unrelated metastases may arise in patients with cutaneous melanoma. Am. J. Surg. Pathol. 31, 1029-1037 (2007).
8. Wilmott JS, Tembe V, Howle JR et al. Intratumoral molecular heterogeneity in a BRAFmutant, BRAF inhibitor-resistant melanoma: A case illustrating the challenges for personalized medicine. Mol. Cancer Ther. 11(12), 2704-2708 (2012).
9. Katona TM, O'Malley DP, Cheng L et al. Loss of heterozygosity analysis identifies genetic abnormalities in mycosis fungoides and specific loci associated with disease progression. Am. J. Surg. Pathol. 31, 1552-1556 (2007).
10. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat. Rev. Cancer 12, 349-361 (2012).
11. Poulikakos PI, Persaud Y, Janakiraman M et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390 (2011).
12. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N. Engl J. Med. 353, 2135-2147 (2005).
13. Hodis E, Watson IR, Kryukov GV et al. A landscape of driver mutations in melanoma. Cell 150, 251-263 (2012).
14. Molecular Surgical Pathology. Cheng L, Eble JN (Eds). Springer, NY, USA (2012).
15. Molecular Genetic Pathology, 2nd edition. Cheng L, Zhang D, Eble J (Eds). Springer, NY, USA (2013).
16. Sosman JA, Kim KB, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714 (2012).
17. Viros A, Fridlyand J, Bauer J et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 5(6), e120 (2008).
18. Cheng L, Alexander RE, Maclennan GT et al. Molecular pathology of lung cancer: key to personalized medicine. Mod. Pathol. 25, 347-369 (2012).
19. Pritchard CA, Samuels ML, Bosch E, Mcmahon M. Conditionally oncogenic forms of the ARaf and BRaf protein kinases display different biological and biochemical properties in NIH 3T3 cells. Mol. Cell. Biol. 15, 6430-6442 (1995).
20. Artale S, Sartore-Bianchi A, Veronese SM et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J. Clin. Oncol. 26, 4217-4219 (2008).
21. Ayhan A, Kurman RJ, Yemelyanova A et al. Defining the cut point between low-grade and high-grade ovarian serous carcinomas: A clinicopathologic and molecular genetic analysis. Am. J. Surg. Pathol. 33, 1220-1224 (2009).
22. Yip L, Nikiforova MN, Carty SE et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery 146, 1215-1223 (2009).
23. Tiacci E, Trifonov V, Schiavoni G et al. BRAF mutations in hairy-cell leukemia. N. Engl J. Med. 364, 2305-2315 (2011).
24. Flaherty KT, Fisher DE. New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances. Clin. Cancer Res. 17, 4922-4928 (2011).
25. Menzies AM, Haydu LE, Visintin L et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAFmutant metastatic melanoma. Clin. Cancer Res. 18, 3242-3249 (2012).
26. Amanuel B, Grieu F, Kular J, Millward M, Iacopetta B. Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Pathology 44, 357-359 (2012).
27. Anderson S, Bloom KJ, Vallera DU et al. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. Arch. Pathol. Lab. Med. 136, 1385-1391 (2012).
28. Ross AL, Sanchez MI, Grichnik JM. Molecular nevogenesis. Dermatol. Res. Pract. 2011, 463184 (2011).
29. Taube JM, Begum S, Shi C, Eshleman JR, Westra WH. Benign nodal nevi frequently harbor the activating V600E BRAF mutation. Am. J. Surg. Pathol. 33, 568-571 (2009).
30. Bauer J, Curtin JA, Pinkel D, Bastian BC. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J. Invest. Dermatol. 127, 179-182 (2007).
31. Wagle N, Emery C, Berger MF et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085-3096 (2011).
32. Villanueva J, Vultur A, Lee JT et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF1R/PI3K. Cancer Cell 18, 683-695 (2010).
33. Johannessen CM, Boehm JS, Kim SY et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972 (2010).
34. Greger JG, Eastman SD, Zhang V et al. Combinations of BRAF, MEK, and PI3K/ mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther. 11, 909-920 (2012).
35. Gowrishankar K, Snoyman S, Pupo GM, Becker TM, Kefford RF, Rizos H. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. J. Invest. Dermatol. 132, 1850-1859 (2012).
36. Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107-114 (2012).
37. Dahlman KB, Xia J, Hutchinson K et al. BRAFL597 mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov. 2, 791-797 (2012).
38. Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. (2012).
39. Garraway LA, Baselga J. Whole-genome sequencing and cancer therapy: is too much ever enough? Cancer Discov. 2, 766-768 (2012).
40. Ribas A, Hersey P, Middleton MR et al. New challenges in endpoints for drug development in advanced melanoma. Clin. Cancer Res. 18, 336-341 (2012).